Ibrexafungerp citrate (Synonyms: MK 3118 citrate; SCY-078 citrate)

Name: Ibrexafungerp citrate
Brand: MedChemExpress
SKU: HY-107126A
Rating: 4.5 (1 reviews)

Cat. No.: HY-107126A Purity: 99.10%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections.

For research use only. We do not sell to patients.

Ibrexafungerp citrate Chemical Structure

CAS No. : 1965291-08-0

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 933	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 933	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 570	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 920	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1850	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 3000	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 4800	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Ibrexafungerp citrate:

Ibrexafungerp Get quote
Ibrexafungerp phosphate Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Ibrexafungerp citrate (MK 3118 citrate) leads to fungicidal activity against various Candida spp., with a minimum inhibitory concentration (MIC50) of 0.5 µg/mL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pharmacokinetic Analysis
Ibrexafungerp citrate (MK 3118 citrate) exhibits oral bioavailability (mouse 51%, rat 45%, dog 35%) following oral administration (mouse 1 mg/kg, rat 5 mg/kg and dog 5 mg/kg)^[3].
Ibrexafungerp citrate (MK 3118 citrate) exhibits moderate half-lives (mouse 5.5, rat 8.7 and, dog 9.3 h) due to high plasma clearance (0.68, 0.44, and 0.45 L/h/kg respectively) combined with large volumes of distribution (5.3, 4.7, and 4.1 L/kg respectively) following intravenous administration (mouse 1 mg/kg, rat 5 mg/kg and dog 5 mg/kg)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female CD1 mice, Male and female Han Wister rats, Male and female beagle dogs^[3]
Dosage:	Mice (1 mg/kg), rats (5 mg/kg) and dogs (5 mg/kg)
Administration:	Intravenous (i.v.) or oral gavage
Result:	T_1/2s of 5.5, 8.7, and 9.3 h for mice, rats, and dogs, respectively.

Molecular Weight

922.16

Formula

C₅₀H₇₅N₅O₁₁

CAS No.

1965291-08-0

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12[C@@](CC3)([H])[C@@](C[C@](N4C(C5=CC=NC=C5)=NC=N4)([H])[C@@H]1OC[C@](C)(N)C(C)(C)C)(COC2)C([C@@]3([H])[C@]6(CC[C@]7(C)[C@H](C)C(C)C)C)=CC[C@]6([C@@H]7C(O)=O)C.OC(CC(C(O)=O)(O)CC(O)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (108.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.0844 mL	5.4221 mL	10.8441 mL
5 mM	0.2169 mL	1.0844 mL	2.1688 mL
10 mM	0.1084 mL	0.5422 mL	1.0844 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.10%

Select Batch:

Data Sheet (283 KB) SDS (393 KB)

COA (263 KB) HNMR (308 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. James M Apgar, et al. Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor. Bioorg Med Chem Lett. 2021 Jan 15;32:127661. [Content Brief]

[2]. Mahmoud Ghannoum, et al. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections. Antibiotics (Basel). 2020 Aug 25;9(9):539. [Content Brief]

[3]. Stephen A Wring, et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.0844 mL	5.4221 mL	10.8441 mL	27.1103 mL
	5 mM	0.2169 mL	1.0844 mL	2.1688 mL	5.4221 mL
	10 mM	0.1084 mL	0.5422 mL	1.0844 mL	2.7110 mL
	15 mM	0.0723 mL	0.3615 mL	0.7229 mL	1.8074 mL
	20 mM	0.0542 mL	0.2711 mL	0.5422 mL	1.3555 mL
	25 mM	0.0434 mL	0.2169 mL	0.4338 mL	1.0844 mL
	30 mM	0.0361 mL	0.1807 mL	0.3615 mL	0.9037 mL
	40 mM	0.0271 mL	0.1356 mL	0.2711 mL	0.6778 mL
	50 mM	0.0217 mL	0.1084 mL	0.2169 mL	0.5422 mL
	60 mM	0.0181 mL	0.0904 mL	0.1807 mL	0.4518 mL
	80 mM	0.0136 mL	0.0678 mL	0.1356 mL	0.3389 mL
	100 mM	0.0108 mL	0.0542 mL	0.1084 mL	0.2711 mL

Ibrexafungerp citrate Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ibrexafungerp1965291-08-0MK 3118SCY-078MK3118MK-3118SCY078SCY 078Fungalβ-1,3-glucanantifungalcandidaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ibrexafungerp citrate (Synonyms: MK 3118 citrate; SCY-078 citrate)

Customer Review

Other Forms of Ibrexafungerp citrate:

Ibrexafungerp citrate Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Ibrexafungerp citrate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ibrexafungerp citrate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report